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1. Introduction
Antibiotic resistance among Enterobacteriaceae is an ever-
increasing concern both in Ireland and worldwide. Infection with
antibiotic-resistant Enterobacteriaceae can lead to treatment fail-
ures due to limited antibiotic treatment options as well as posing
the risk of cross-infection. AmpC b-lactamase producing organ-
isms hydrolyse narrow-, broad- and expanded-spectrum cepha-
losporins and cephamycins (e.g. cefoxitin) and are usually only
susceptible to fourth-generation cephalosporins and carbapenems
[1]. AmpC b-lactamase resistance may be conferred through
chromosomal or plasmid-mediated origins.
The chromosomal ampC gene in Escherichia coli is generally
expressed at low levels, not causing clinical resistance, because the
promoter is weak and the gene contains a transcriptional
attenuator [2]. However, constitutive overexpression of ampC in
E. coli can occur due to either the hyperproduction of a
chromosomally encoded ampC gene or by acquisition of a
transferable ampC gene on a plasmid [3]. The occurrence of ampC
b-lactamases on plasmids presents the threat of spreading this
resistance mechanism to other organisms within a hospital or
geographic region.
Ireland started reporting third-generation cephalosporin sen-
sitivity among E. coli in 2002. Between 2002 and 2010, the
proportion of resistant E. coli increased from 2.2% to 7.7%. There is
limited information with regard to the prevalence and epidemiol-
ogy of plasmid-mediated AmpC (pAmpC) b-lactamases among E.
coli in Ireland. Roche et al. reported that 3% of Klebsiella pneumoniae
collected prospectively from April 2005 to March 2007 carried
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This study determined the prevalence and distribution of plasmid-mediated AmpC (pAmpC)
b-lactamases in Irish Escherichia coli isolates. Clinical E. coli isolates (n = 95) that were intermediate
or resistant to cefoxitin and/or flagged by VITEK1 2 as potential AmpC-producers underwent
confirmation using a MASTDISCSTM ESBL and AmpC Detection Kit. Multiplex PCR capable of detecting
family-specific plasmid ampC genes was performed to detect the presence of these genes. Five PCR-
negative isolates were selected for promoter analysis. PFGE and MLST were performed on E. coli isolates
that harboured a plasmid ampC gene to determine their clonal relatedness. Plasmid ampC genes were
detected in 19% (18/95) of phenotypic AmpC producing E. coli isolates. The CIT group was the most
common plasmid family type (n = 14); DHA (n = 3) and ACC (n = 1) groups were also detected. Promoter
analysis showed that four isolates had multiple point mutations and one had a 1 bp insertion in the 10
box. PFGE demonstrated a polyclonal pattern for E. coli isolates. Furthermore, with the exception of two
isolates with an identical sequence type (ST720), MLST analysis revealed that these isolates were not
clonally related. This study revealed that there was a marked prevalence of pAmpC E. coli among
phenotypic AmpC producing E. coli isolates but no evidence of cross-transmission of a single strain.
Establishing the prevalence and clonality of these organisms is important in order to implement
evidence-based infection control measures that reduce the spread of pAmpC b-lactamase resistance in
the hospital environment.
 2015 Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and
Cancer.
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pAmpC in Ireland [4]. A study undertaken by the UK Antibiotic
Resistance Monitoring and Reference Laboratory in 2007 reported
a prevalence rate of pAmpC of 49% (67/135) and 55% (21/38)
among cephalosporin- and cefoxitin-resistant E. coli and Klebsiella
spp., respectively [5]. It is important to identify the occurrence of
pAmpC in these organisms in order to implement necessary
infection control measures.
The aim of this study was to establish the prevalence and
clonality of clinical isolates of pAmpC producing E. coli in two south
Dublin hospitals. E. coli isolates that were intermediate or resistant
to cefoxitin and/or were flagged by the VITEK1 2 system as
potential AmpC-producers underwent a phenotypic test to confirm
the production of an AmpC b-lactamase. Multiplex PCR was
subsequently carried out to identify the presence of plasmid ampC
genes among isolates that demonstrated an AmpC phenotype.
Finally, the genetic relatedness of pAmpC producing E. coli isolates
was investigated through pulsed-field gel electrophoresis (PFGE)
and multilocus sequence typing (MLST).
2. Methods
2.1. Bacterial strains and antimicrobial susceptibility testing
A total of 95 non-duplicate AmpC producing E. coli isolates were
collected from two hospitals in Dublin (Ireland) from March
2011 to October 2012.
Identification and susceptibility testing were performed by the
VITEK1 2 Compact (bioMe´rieux, Marcy-l’E´toile, France) and the
results were interpreted according to European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints
v.2.0 and EUCAST Expert rules v.1.0 [6]. The advanced expert
system (AES) of the VITEK1 2 Compact identified the isolates as
potential AmpC producers on the basis of an antimicrobial
susceptibility pattern that is compatible with an AmpC producing
phenotype, i.e. resistance to first- and second-generation cepha-
losporins, resistance to one or more of the third-generation
cephalosporins and/or reduced susceptibility to cefoxitin, and
sensitivity to the fourth-generation cephalosporin cefepime.
2.2. Phenotypic AmpC b-lactamase detection
Isolates were confirmed phenotypically as AmpC b-lactamase
producers by the MASTDISCSTMESBL and AmpC Detection Kit (MAST
Group Ltd., Merseyside, UK). The MASTDISCSTM kit is an inhibitor-
based test that detects the presence of AmpC b-lactamases and
extended-spectrumb-lactamases (ESBLs). Briefly, a Mueller–Hinton
agar plate (L.I.P. Diagnostic Services, Galway, Ireland) was inoculat-
ed with a 0.5 McFarland standard suspension of a test isolate. The A
(10 mg cefpodoxime), B (10 mg cefpodoxime + the ESBL inhibitor
clavulanic acid), C (10 mg cefpodoxime + the AmpC inhibitor
cloxacillin) and D (10 mg cefpodoxime + ESBL and AmpC inhibitors)
disks were applied onto the plate. The zone of inhibition around each
disc was measured following 18–24 h of incubation at 37 8C in air
and was interpreted according to the manufacturer’s instructions.
2.3. Multiplex PCR
Isolates confirmed as AmpC b-lactamase producers by the
phenotypic MASTDISCSTM ESBL and AmpC Detection Kit were
screened for the presence of a plasmid-borne ampC gene using a
multiplex PCR assay developed by Pe´rez-Pe´rez and Hanson [7]. This
PCR utilises six primer sets to detect the six phylogenetic families
of plasmid ampC b-lactamase genes (i.e. blaFOX, blaCIT, blaDHA,
blaEBC, blaMOX and blaACC) on the basis of amplicon size and was
performed as described previously [7]. A representative group of
blaCIT PCR products (n = 7) were randomly selected for sequencing.
Sequence alignments and analysis were performed using the NCBI
BLAST programme (http://www.ncbi.nlm.nih.gov).
2.4. Promoter analysis
Five of the multiplex PCR negative isolates were analysed for
ampC promoter mutations, which included promoter PCR,
sequencing of the products and multiple sequence alignment
with the E. coli K12 strain promoter sequence [8].
2.5. Pulsed-field gel electrophoresis
Agarose-embedded plugs containing intact bacterial DNA were
prepared using a CHEF (Contour-Clamped Homogenous Electric
Fields) Mapper Plug Kit (Bio-Rad Laboratories, Hemel Hempstead,
UK) according to the manufacturer’s instructions. Following
overnight digestion of the plugs with Xbal at 37 8C, PFGE was
performed on a CHEF Mapper XA PFGE System (Bio-Rad
Laboratories) according to the PulseNet standardised laboratory
protocol [9]. The electrophoresis conditions were optimised for
separation of the 30–600 kb fragments in a 1% agarose gel with
0.5 TBE [Tris–borate–ethylene diamine tetra-acetic acid (EDTA)]
buffer and a voltage of 6 V/cm for 19 h, with an initial switch time
of 2.2 s and final switch time of 54.2 s. A dendrogram was
constructed using the Dice coefficient with an optimisation of 1%
and a tolerance of 1% in band position difference (FPQuestTM
Software; Bio-Rad Laboratories). The clonal relationship among
isolates was determined according to the criteria of Tenover et al.
[10]. Clonal groups were assigned based on a similarity of 80%
(3 band difference in restriction profile).
2.6. Multilocus sequence typing
Nine E. coli isolates harbouring a plasmid ampC gene were
selected for further characterisation through the E. coli MLST
scheme developed by the Achtman group [11]. The protocol for this
typing method, including the PCR primers, PCR components and
cycling conditions required, was accessed through the online MLST
E. coli database [12]. The PCR products of the seven housekeeping
genes on all nine E. coli isolates were subsequently purified for
sequencing using a QIAquick PCR Purification Kit (QIAGEN, Hilden,
Germany). Sanger sequencing was performed by an external
laboratory (Source BioScience, LifeSciences, Dublin, Ireland) and
the MLST PCR primer pairs were used for the sequencing step. The
sequencing data of each isolate were entered into the E. coli MLST
online database (http://mlst.ucc.ie/mlst/dbs/Ecoli) to give a
distinct allelic number. The alleles for the seven loci were
combined to give an allelic profile or sequence type (ST). The
STs of each of the nine isolates were collated and compared.
3. Results
3.1. Antimicrobial susceptibility testing and MASTDISCSTM
Ninety-five E. coli isolates were identified by the VITEK1
2 system as potential AmpC producers and were phenotypically
confirmed for AmpC production using combination disks. One
isolate was positive for the coexistence of AmpC and ESBL
enzymes. E. coli isolates demonstrated variable resistance to the
third-generation cephalosporins, with some isolates only resistant
to one of either cefotaxime or ceftazidime or sensitive to both.
Isolates that were positive for a plasmid ampC gene generally had
higher minimum inhibitory concentrations (MICs) against the
third-generation cephalosporins than chromosomally mediated
AmpC producing isolates (Table 1). A total of 94% (17/18) and 83%
(15/18) of pAmpC isolates were resistant to ceftazidime and
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cefotaxime, respectively. In contrast, chromosomally mediated
AmpC producing isolates were more sensitive, with only 12% (9/
77) resistant to ceftazidime and 14% (11/77) resistant to
cefotaxime. With the exception of one isolate (E25), AmpC-
producing E. coli isolates in this study were resistant to cefoxitin.
Most isolates (n = 94) were sensitive to the fourth-generation
cephalosporin cefepime, except for one isolate (E23) that was also
non-susceptible to ertapenem. All 95 isolates were sensitive to
meropenem. In addition, many isolates demonstrated multi-
resistance; 16 isolates displayed resistance to the aminoglycoside
gentamicin and 31 isolates were resistant to the fluoroquinolone
ciprofloxacin.
3.2. AmpC multiplex PCR
Of the 95 isolates that were screened for the presence of a
plasmid ampC b-lactamase gene by multiplex PCR, 18 isolates
(19%) were pAmpC positive. The predominant gene was blaCIT,
detected in 14 E. coli isolates (Table 2). Nucleotide sequencing of a
representative group of these isolates (n = 7) revealed 100%
concordance with the blaCMY-2 gene sequence (GenBank accession
no. HQ680723). Other pAmpC genes identified were blaDHA (n = 3)
and blaACC (n = 1). The majority of phenotypic AmpC producing E.
coli isolates were negative for a pAmpC gene, which suggests that
the presence of AmpC could be due to either hyperproduction of
chromosomal AmpC or acquisition of novel plasmids that were not
detected by the multiplex PCR in this study.
3.3. Promoter analysis
Five of the multiplex PCR negative isolates were analysed for
ampC promoter mutations. Four of them had multiple point
mutations in the promoter region and one had a 1-bp insertion in
the 10 box compared with E. coli K12 (Table 3). The predominant
point mutation was at +58, followed by the 35 box.
3.4. Isolates with plasmid-mediated AmpC are genetically unrelated
The 18 E. coli isolates harbouring plasmid ampC genes were not
clonally related by PFGE analysis and revealed <50% sequence
homology. Furthermore, a representative group of nine pAmpC
positive E. coli isolates were typed by MLST. With the exception of
two isolates (isolates 90 and 91), which were ST720, MLST analysis
revealed that these isolates were unrelated (Table 2). Apart from
ST493 and ST3672, all of the MLST types have been previously
detected both in humans and livestock in Europe [12]. ST493 has
been isolated from humans in Japan and ST3672 from wild animals
in China [12].
4. Discussion
Antimicrobial resistance among Enterobacteriaceae is fast
becoming a worldwide public health concern, and AmpC b-
lactamases are an emerging group of antimicrobial resistance
determinants [13]. The occurrence of ampC genes on plasmids
presents a great challenge to infection control because plasmid-
mediated genes can spread to other organisms within a hospital or
geographic region. The lack of a widely accepted phenotypic AmpC
b-lactamase detection method greatly hinders accurate detection
and surveillance of AmpC producers and hence the ability to limit
the spread of pAmpC resistance. This study was designed to
determine the prevalence and clonality of pAmpC producing E. coli
in two Dublin hospitals.
Table 1
Minimum inhibitory concentrations (MICs) (in mg/L) of Escherichia coli isolates with
an AmpC phenotype.
Antibiotic pAmpC (n = 18) Chromosomal AmpC (n = 77)
Mode MIC MIC range Mode MIC MIC range
AMP 32 32 32 32
CXM 64 16 to 64 16 4 to 64
CTX 16 1 to 64 1 1 to 16
CAZ 8 1 to 64 1 1 to 64
FEP 1 1–2 1 1
FOX 64 8 to 64 16 4 to 64
MEM 0.25 0.25 0.25 0.25
ETP 0.5 0.5–1 0.5 0.5
GEN 1 1 to 16 1 0.25 to 16
CIP 0.25 0.25 to 4 0.25 0.25 to 4
pAmpC, plasmid-mediated AmpC; AMP, ampicillin; CXM, cefuroxime; CTX,
cefotaxime; CAZ, ceftazidime; FEP, cefepime; FOX, cefoxitin; MEM, meropenem;
ETP, ertapenem; GEN, gentamicin; CIP, ciprofloxacin.
Table 2
Antimicrobial susceptibility and sequence types (STs) by multilocus sequence typing of plasmid-mediated AmpC-producing Escherichia coli (n = 18).
Isolate MIC (mg/L) AmpC multiplex
PCR (plasmid
blaAmpC)
ST
AMP CXM CAZ CTX FOX FEP MER ETP GEN CIP
E05 >32 16 4 8 >64 1 0.25 0.5 >16 >4 CIT NT
E16 >32 >64 >64 >64 32 1 0.25 0.5 >16 >4 CIT NT
E18 >32 16 4 4 32 1 0.25 0.5 1 >4 CIT NT
E19 >32 >64 >64 >64 >64 1 0.25 0.5 1 0.5 CIT NT
E23 >32 >64 >64 >64 >64 2 0.25 1 1 0.25 CIT NT
E25 >32 32 32 8 8 1 0.25 0.5 1 >4 ACC NT
E27 >32 16 4 1 >64 1 0.25 0.5 >16 0.25 DHA NT
E35 >32 >64 >64 16 >64 1 0.25 0.5 >16 >4 CIT NT
E53 >32 >64 >64 32 >64 1 0.25 0.5 1 0.25 CIT NT
E90 >32 >64 >64 16 >64 1 0.25 0.5 1 0.25 CIT ST720 (35-3-58-6-5-16-4)
E91 >32 >64 1 1 >64 1 0.25 0.5 8 0.25 CIT ST720 (35-3-58-6-5-16-4)
E113 >32 >64 4 4 >64 1 0.25 0.5 1 >4 DHA ST38 (4-26-2-25-5-5-19)
E130 >32 32 16 8 >64 1 0.25 0.5 1 0.25 CIT ST3672 (76-13-190-13-17-30-25)
B6 >32 16 16 4 >64 1 0.25 0.5 1 >4 CIT ST10 (10-11-4-8-8-8-2)
B7 >32 >64 16 1 >64 1 0.25 0.5 >16 0.25 DHA ST493 (40-13-9-13-16-10-9)
B10 >32 16 16 8 >64 1 0.25 0.5 1 0.25 CIT ST92 (40-14-19-36-23-11-10)
B12 >32 32 16 8 >64 1 0.25 0.5 1 0.25 CIT ST906 (6-4-3-16-11-8-6)
B18 >32 >64 16 8 >64 1 0.25 0.5 1 >4 CIT ST354 (85-88-78-29-59-58-62)
MIC, minimum inhibitory concentration; AMP, ampicillin; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; FOX, cefoxitin; FEP, cefepime; MEM, meropenem; ETP,
ertapenem; GEN, gentamicin; CIP, ciprofloxacin; NT, not tested.
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A total of 95 E. coli clinical isolates phenotypically identified as
AmpC b-lactamase producers by VITEK1 2 and combination disks
were included in this study. Whilst the majority of them were
identified as possible chromosomal AmpC hyperproducers
(n = 77), a total of 18 isolates (19%) were pAmpC producers. This
is compared with a study undertaken by the UK antimicrobial
reference laboratory including Irish isolates that reported a
prevalence rate of pAmpC of 49% (67/135) among cephalospo-
rin-resistant E. coli spp. [5]. The higher prevalence rate detected in
the UK study could potentially be explained by the fact that
microbiology laboratories would only send the most resistant
isolates for further analysis to reference laboratories, whereas in
the current study serial clinical isolates exhibiting an AmpC
phenotype were collected. Other studies carried out in hospital
laboratories and similar in design to this study have revealed
various prevalence rates. For example, a study from Denmark
reported a similar prevalence to our data, in which 17% (4/24) of E.
coli carried a plasmid ampC gene [14], whilst a study in Switzerland
reported a higher prevalence at 38% (8/21) [15].
The predominant ampC gene detected in this study was blaCIT,
identified in 14 E. coli isolates. Nucleotide sequencing of a
representative group of these isolates (n = 7) revealed the
blaCMY-2 gene. This observation is consistent with many other
studies worldwide in which CMY-2 is the most commonly acquired
plasmid and widely geographically distributed AmpC enzyme
[5,15–22].
In addition, blaDHA (n = 3) and blaACC (n = 1) were also detected.
The CIT, DHA and ACC AmpC enzymes have been previously
identified among E. coli and K. pneumoniae isolates in Ireland
[4,5]. The isolate (E25) that harboured a blaACC gene in this study
was susceptible to cefoxitin, which correlates with many studies
showing that isolates with ACC enzyme are sensitive to cefoxitin
[4,23]. It is important to consider that the use of cefoxitin
resistance as a screening marker may be compromised by isolates
producing plasmid-encoded ACC AmpC b-lactamases that are
sensitive to cefoxitin.
This study revealed that pAmpC producing E. coli isolates
displayed higher MICs to the third-generation cephalosporins and
cefoxitin than chromosomal AmpC hyperproducing E. coli
(Table 1). Concomitant resistance to cefotaxime, ceftazidime and
cefoxitin in phenotypic AmpC-producing E. coli isolates was
suggestive of pAmpC production. Hence, whilst routine molecular
testing for pAmpC in E. coli is currently unavailable in Ireland, the
susceptibility profile of a phenotypically confirmed AmpC produc-
ing E. coli may help to distinguish between pAmpC production and
chromosomal AmpC hyperproduction.
Co-resistance to other antimicrobials was frequently observed
among these isolates. For example, ciprofloxacin resistance was
observed in 33% (31/95) of AmpC producers in this study. A rising
trend of fluoroquinolone resistance among AmpC producing E. coli
has been reported by Simner et al. [3].
The coexistence of multiple resistance mechanisms in an
organism is a concern as multidrug resistance can severely limit
therapeutic options. In this study, co-production of AmpC and
ESBL was detected in one isolate. Continuous resistance surveil-
lance and the implementation of infection control measures are
important to reduce the spread of multidrug-resistant organisms.
Five of the multiplex PCR negative isolates were analysed for ampC
promoter mutations and the results suggested that they are
common mutations as they were also identified by Haldorsen
et al., who reported three different mechanisms for increased
expression of chromosomal ampC genes including multiple point
mutations (positions 1, 18, 42, 82, 88 and +58) and single
nucleotide or insertion sequence (IS) element insertions between
the 35 and 10 boxes [16]. Further work is required to
investigate the role of ampC promoter mutations in AmpC
hyperproduction.
Detection of a plasmid ampC gene in an AmpC producing
organism provides a valuable insight into the resistance mecha-
nism of an isolate and the potential for this resistance to spread. It
is equally important to understand whether antimicrobial resis-
tance is due to the transmission of resistance genes from organism
to organism or through the transmission of a single resistant strain.
Molecular typing by PFGE and MLST was performed in this study to
investigate whether pAmpC isolates were clonally related and
hence the result of the spread of a single strain. PFGE showed that
the pAmpC producers (n = 18) represented different DNA restric-
tion patterns with <50% fragments sharing homology. These
results suggest that the incidence of transferable AmpC in E. coli
was the result of a mobile element rather than the spread of a
single clone.
MLST was carried out on a representative group (n = 9) of
pAmpC E. coli isolates in this study. MLST was performed due to
the worldwide clonal dissemination of E. coli ST131 and recent
detection of pAmpC b-lactamases among E. coli ST131 [24,25].
Among the nine selected E. coli isolates, MLST identified eight
different STs. The pandemic E. coli clone ST131 was not detected
in this study. Two isolates (isolates E90 and E91) had the same
allelic profiles and therefore the same ST (ST720). These two
isolates only displayed 40% similarity by PFGE, highlighting that
MLST has a lower discriminating ability compared with PFGE, as
reported in previous studies [26–28]. The remaining seven
isolates had different individual allelic profiles and therefore
different STs. The ST38 isolate in this study (isolate E113) carried
a blaDHA plasmid ampC gene. However, in two separate studies,
pAmpC E. coli isolates related to the sequence type complex (STC)
38 instead harboured a blaCIT plasmid ampC gene [24,25]. This
illustrates how plasmids can spread among isolates and also that
this globally distributed E. coli strain can acquire different
plasmid ampC genes. Other strains identified in this study (ST92,
ST493, ST720, ST906 and ST3672) have not been previously
reported among pAmpC producing E. coli in the literature and
could indicate that there has been further spread of plasmid ampC
genes among E. coli strains.
In conclusion, this study revealed that there was a prevalence of
19% of pAmpC producing E. coli among isolates displaying an AmpC
phenotype in two Dublin hospitals. The fact that the isolates
investigated by PFGE and MLST were not clonally related
demonstrates that pAmpC resistance was due to the transfer of
plasmids among isolates rather than the spread of a single
organism. As both hospitals do not routinely isolate patients
harbouring E. coli with an AmpC phenotype, the lack of evidence for
cross-infection by PFGE was reassuring. These findings emphasise
the importance of investigating AmpC b-lactamases in clinical
isolates at a molecular level, although routine molecular testing is
currently beyond the scope of Irish diagnostic laboratories. In this
way, informed and evidence-based infection control polices can be
introduced to reduce the spread of pAmpC resistance in hospitals
and limit the movement of this resistance mechanism.
Table 3
Mutations identified in the Escherichia coli ampC promoter region.
Isolate
number
Mutationsa
E7 88 (C ! T), 82 (A ! G), 18 (G ! A), 1 (C ! T), +58 (C ! T)
E10 35 box (T ! A), +58 (G ! T), +63 (T ! C)
E31 +70 (C ! T)
Attenuator: +21 (C ! T), +25 (T ! G), +26 (A ! T), +31 (G ! A)
E36 35 box (T ! A), +58 (C ! T), +63 (T ! C)
E46 1 bp (T) insertion in the 10 box
a Compared with E. coli K12.
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